It was previously reported that CDK4/6 inhibitors activated the PI3K/AKT pathway through the phosphorylation of S473/T308 on AKT and CDK4/6 and PI3K inhibitor combination reduced AKT phosphorylation in PIK3CA mutated breast cancer cell lines. This evidence concerns the gene CDK4 and breast carcinoma.